Teva Acquires Auspex for its Molecules

Teva Pharmaceuticals Industries (NYSE: TEVA) boasts that it has a portfolio of more than 1,000 molecules, which it uses to produce a wide range of generic products. Last week, the company decided it needed a few more molecules, so it agreed to pay $3.2 billion ($101 per share in cash) for Auspex Pharmaceuticals (NASDAQ: ASPX), which has 61 molecules aimed at various diseases of the central nervous system. Of course, there was a special molecule that attracted Teva: SD-809, which reported positive results from its Phase 3 clinical trial last year, as a treatment for Huntington’s disease.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *